Adverse events104

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 104

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anemia	Blood and lymphatic system disorders	High Dose Treatment After Receiving the Standard Dose (Nelfinavir Mesylate)	6	31	8
other	Anemia	Blood and lymphatic system disorders	Standard Dose Treatment (Nelfinavir Mesylate)	0	36	0
other	DIARRHEA	Gastrointestinal disorders	High Dose Treatment After Receiving the Standard Dose (Nelfinavir Mesylate)	24	31	51
other	DIARRHEA	Gastrointestinal disorders	Standard Dose Treatment (Nelfinavir Mesylate)	3	36	4
other	DIZZINESS	Nervous system disorders	High Dose Treatment After Receiving the Standard Dose (Nelfinavir Mesylate)	4	31	4
other	DIZZINESS	Nervous system disorders	Standard Dose Treatment (Nelfinavir Mesylate)	0	36	0
other	DRY SKIN	Skin and subcutaneous tissue disorders	High Dose Treatment After Receiving the Standard Dose (Nelfinavir Mesylate)	2	31	2
other	DRY SKIN	Skin and subcutaneous tissue disorders	Standard Dose Treatment (Nelfinavir Mesylate)	0	36	0
other	FATIGUE	General disorders	High Dose Treatment After Receiving the Standard Dose (Nelfinavir Mesylate)	2	31	3
other	FATIGUE	General disorders	Standard Dose Treatment (Nelfinavir Mesylate)	0	36	0
other	FLATULENCE	Gastrointestinal disorders	High Dose Treatment After Receiving the Standard Dose (Nelfinavir Mesylate)	2	31	2
other	FLATULENCE	Gastrointestinal disorders	Standard Dose Treatment (Nelfinavir Mesylate)	0	36	0
other	HYPERGLYCEMIA	Metabolism and nutrition disorders	High Dose Treatment After Receiving the Standard Dose (Nelfinavir Mesylate)	4	31	4
other	HYPERGLYCEMIA	Metabolism and nutrition disorders	Standard Dose Treatment (Nelfinavir Mesylate)	0	36	0
other	HYPERTRIGLYCERIDEMIA	Metabolism and nutrition disorders	High Dose Treatment After Receiving the Standard Dose (Nelfinavir Mesylate)	7	31	8
other	HYPERTRIGLYCERIDEMIA	Metabolism and nutrition disorders	Standard Dose Treatment (Nelfinavir Mesylate)	0	36	0
other	MYALGIA	Musculoskeletal and connective tissue disorders	High Dose Treatment After Receiving the Standard Dose (Nelfinavir Mesylate)	2	31	2
other	MYALGIA	Musculoskeletal and connective tissue disorders	Standard Dose Treatment (Nelfinavir Mesylate)	0	36	0
other	NAUSEA	Gastrointestinal disorders	High Dose Treatment After Receiving the Standard Dose (Nelfinavir Mesylate)	8	31	8
other	NAUSEA	Gastrointestinal disorders	Standard Dose Treatment (Nelfinavir Mesylate)	2	36	2

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03077451/events

API reference For AI assistants

Adverse events104

Sources 3

Read this list from software.